It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Sister chromatid exchanges (SCEs) are products of joint DNA molecule resolution, and are considered to form through homologous recombination (HR). Indeed, SCE induction upon irradiation requires the canonical HR factors BRCA1, BRCA2 and RAD51. In contrast, replication-blocking agents, including PARP inhibitors, induce SCEs independently of BRCA1, BRCA2 and RAD51. PARP inhibitor-induced SCEs are enriched at difficult-to-replicate genomic regions, including common fragile sites (CFSs). PARP inhibitor-induced replication lesions are transmitted into mitosis, suggesting that SCEs can originate from mitotic processing of under-replicated DNA. Proteomics analysis reveals mitotic recruitment of DNA polymerase theta (POLQ) to synthetic DNA ends. POLQ inactivation results in reduced SCE numbers and severe chromosome fragmentation upon PARP inhibition in HR-deficient cells. Accordingly, analysis of CFSs in cancer genomes reveals frequent allelic deletions, flanked by signatures of POLQ-mediated repair. Combined, we show PARP inhibition generates under-replicated DNA, which is processed into SCEs during mitosis, independently of canonical HR factors.
Sister chromatid exchanges (SCEs) are considered to be products of homologous recombination repair. The authors show that SCEs can arise independently of homologous recombination due to processing of replication intermediates during mitosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 University Medical Center Groningen, University of Groningen, the Netherlands, Department of Medical Oncology, Groningen, the Netherlands (GRID:grid.4830.f) (ISNI:0000 0004 0407 1981); University Medical Center Groningen, University of Groningen, the Netherlands, Department of Genetics, Groningen, the Netherlands (GRID:grid.4830.f) (ISNI:0000 0004 0407 1981)
2 University Medical Center Groningen, University of Groningen, the Netherlands, Department of Medical Oncology, Groningen, the Netherlands (GRID:grid.4830.f) (ISNI:0000 0004 0407 1981); The University of Edinburgh. Crewe Road South, Edinburgh, MRC Human Genetics Unit, Institute of Genetics and Cancer, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
3 University Medical Center Groningen, University of Groningen, European Institute for the Biology of Ageing, Groningen, the Netherlands (GRID:grid.4830.f) (ISNI:0000 0004 0407 1981); University of Washington School of Medicine, Department of Genome Sciences, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
4 Erasmus University Medical Center, Department of Molecular Genetics, Erasmus MC Cancer Institute, Rotterdam, the Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)
5 Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (GRID:grid.487647.e); Oncode Institute, Utrecht, the Netherlands (GRID:grid.499559.d)
6 University Medical Center Groningen, University of Groningen, the Netherlands, Department of Medical Oncology, Groningen, the Netherlands (GRID:grid.4830.f) (ISNI:0000 0004 0407 1981)
7 Leiden University Medical Center, Department of Human Genetics, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978)
8 University Medical Center Groningen, University of Groningen, European Institute for the Biology of Ageing, Groningen, the Netherlands (GRID:grid.4830.f) (ISNI:0000 0004 0407 1981)
9 Oncode Institute, Utrecht, the Netherlands (GRID:grid.499559.d); Hubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, the Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352)
10 University Medical Center Groningen, University of Groningen, European Institute for the Biology of Ageing, Groningen, the Netherlands (GRID:grid.4830.f) (ISNI:0000 0004 0407 1981); Terry Fox Laboratory, BC Cancer Agency, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000); University of British Columbia, Department of Medical Genetics, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)